Table 3

Comparative summary of the evidence for CSF and blood biomarkers in DLB and delirium34–52

BiomarkerFluidEvidence in DLBEvidence in delirium
AcetylcholineCSFNot studiedNo association65
Some association with delirium + AD/VaD65
BloodNot studied↑SAA in delirium versus controls47
↑SAA in greater number of delirium symptoms47
↑SAA in acute delirium78
↓SAA following resolution of delirium78
⇔SAA in delirium versus controls and delirium±dementia79
↓AChE/BuChE in delirium80
α-synucleinCSF↓α-syn in DLB versus AD/control 67 68
⇔α-syn in DLB versus AD,69 VaD, FTLD70
↓α-syn in mild DLB71
↓α-syn in longer DLB duration69
Not studied
Blood↓α-syn in DLB versus controls82Not studied
AmyloidCSF↓β-amyloid in DLB versus controls74
↑Ab-ox in DLB versus controls46
Not studied
TauCSF↓Tau in DLB versus AD46 72No association with delirium73
Inflammatory markersCSF↑IL in DLB versus controls (not significant)76↑IL-6 and IL-8 in delirium versus controls77
Blood↑TNF-α associated with neuropsychiatric symptoms in mild/moderate DLB87
↑IL-6 associated with poor cognitive function at baseline87
↑IL-6 and IL-8 in delirium versus controls84 85
↑IL-6 during delirium85
↑IL-8 before delirium85
↑IL-6 in hyper versus hypoactive delirium85
⇔ IL in delirium86
  • Ab-ox, β-amyloid peptide; BuChE, butylcholinesterase; DLB, dementia with Lewy Bodies; FTLD, frontotemporal lobe dementia; IL, interleukin; SAA, serum anticholinergic activity; TNF-α, tumour necrosis factor α; VaD, vascular dementia.